Angiotensin converting enzyme defects in shock: implications for future therapy

Lakhmir S. Chawla¹²*, Steve Chen², Rinaldo Bellomo³ and George F. Tidmarsh²⁴

Keywords: Angiotensin insufficiency, ACE defect, Vasodilatory, Bradykinin, Vasodilatory shock, Sepsis

Background
Patients who develop vasodilatory shock, particularly when caused by an inflammatory condition like sepsis or pancreatitis, have evidence of significant endothelial injury as manifested by coagulation disorders and increased capillary permeability [1, 2]. Since angiotensin converting enzyme (ACE) activity is primarily endothelium membrane-bound [3], patients with vasodilatory shock may develop an ACE defect [4, 5]. The pulmonary and renal capillary beds hold the majority of endothelium-bound ACE and patients with acute respiratory distress syndrome (ARDS) have increasing ACE insufficiency with increased severity of lung injury [5, 6]. Moreover, previous studies have demonstrated that endotoxemia causes a decrease in ACE function [7, 8], and, finally, ACE function has been shown to be important in sepsis outcomes [5, 9, 10]. Based on these findings, investigators from the first ATHOS trial have suggested that endothelial dysfunction in vasodilatory shock may cause a significant ACE defect that results in angiotensin II (ANG-2) insufficiency [4].

Main text
In order to test this hypothesis, as part of the ATHOS-3 trial, endogenous ANG-1 and ANG-2 levels were measured prior to study drug infusion at baseline and again 3 h after initiation of exogenous ANG-2 or placebo. One goal of these assessments was to determine if ACE function, as measured by the ANG-1 and ANG-2 levels, was normal. In healthy patients, ANG-2 levels are generally higher than ANG-1 levels [11]. In the ATHOS-3 trial, ANG-1 and ANG-2 levels were significantly elevated with the ANG-1 levels much more elevated than ANG-2 levels, leading to a relative ANG-2 deficiency [12]. This finding is consistent with other studies showing decreased ACE activity in vasodilatory shock and implies that ACE is highly dysregulated in this setting [5, 6]. An unexpected finding was change in ANG-1 at 3 h after baseline. As expected, patients who received placebo did not have a significant change from baseline to 3 h in ANG-1 (median (IQR) values were 238 (75–653) at baseline and 218 (76–553) at 3 h). However, patients who received exogenous ANG-2 demonstrated a significant decrease in ANG-1 levels (the median (IQR) values were 260 (72–679) at baseline and 166 (47–383) at 3 h, p < 0.0001). We hypothesize that this rapid decrease in ANG-1 may be mediated by a biofeedback mechanism: exogenous ANG-2 causes engagement of the ANG-2 type 1 receptor, resulting in increased blood pressure and decreased production of angiotensinogen and/or renin (Fig. 1a, b).

Studies of hypertension patients have shown that ACE inhibition causes increases in bradykinin, ANG-1, and other angiotensin peptides such as ANG 1-7 [11]. ANG 1-7 has been shown to cause vasodilation and to decrease blood pressure [13] (Fig. 2a). Similarly, bradykinin, an ACE substrate, has vasodilatory properties [14, 15]. These data suggest that patients with ACE defect and vasodilatory shock may suffer from a simultaneous excess of the vasodilatory mediators normally metabolized by ACE and a lack of ANG-2 generation. The addition of exogenous ANG-2 in this subset of patients may provide a dual benefit by...
ameliorating the ANG-2 insufficiency, thereby improving blood pressure and reducing vasodilatory angiotensins. The decrease in vasodilatory angiotensins, which are also ACE substrates, may, in turn, improve ACE availability and increase bradykinin degradation (Fig. 2b). This concept is a preliminary hypothesis that will require further investigation. However, if this mechanism can be verified, exogenous ANG-2 therapy may logically provide a therapeutic option for vasodilatory shock patients with ACE defects. Moreover, therapies that utilize agents to decrease vasodilatory ACE substrates like recombinant ACE, ACE-2, or renin inhibitors (i.e., aliskerin) could be combined with exogenous ANG-2 to further potentiate this therapeutic approach. Similarly, treatment with exogenous ANG-2 may even have the potential to treat ACE inhibitor-associated angioedema by decreasing vasodilatory angiotensins and bradykinin levels.

Conclusions

Endothelial injury during shock may lead to ACE defects, which in turn may cause an increase in vasodilatory mediators that are normally metabolized by ACE and a relative or absolute decrease in ANG-2. These pathophysiological derangements may be beneficially affected by ANG-2 infusion. This mechanism of action in shock justifies further investigation of ACE activity, bradykinin levels, and ANG 1-7 levels in vasodilatory shock and may be an important target for future therapeutic intervention.

Abbreviations

ACE: Angiotensin converting enzyme; ANG: Angiotensin; ARDS: Acute respiratory distress syndrome

Acknowledgements

The authors would like to acknowledge medical writing support provided by Emily Plummer, PhD, who is employed by La Jolla Pharmaceutical Company.

Funding

The ATHOS-3 study was sponsored by La Jolla Pharmaceutical Company.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Trial registration
NCT02338843. Registered 1 January 2015, https://clinicaltrials.gov/ct2/show/NCT02338843.

Authors’ contributions
All authors were involved in data interpretation and contributed to writing the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The ATHOS-3 protocol was approved by a research ethics board at each participating institution. The study was conducted in accordance with Good Clinical Practice guidelines, applicable local regulations, and the ethical principles described in the Declaration of Helsinki. Written informed consent was obtained from all patients or their legal surrogates.

Consent for publication
Not applicable.

Competing interests
LC, SC, and GT are employees and shareholders of La Jolla Pharmaceutical Company.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Veterans Affairs Medical Center, San Diego, CA, USA. 2La Jolla Pharmaceutical Company, 4550 Towne Centre Court, San Diego, CA 92121, USA. 3School of Medicine, The University of Melbourne, Parkville, Melbourne, VIC, Australia. 4Stanford School of Medicine, Stanford, CA, USA.

Received: 22 August 2018 Accepted: 24 September 2018
Published online: 28 October 2018

References
1. Levi M, van der Poll T. Endothelial injury in sepsis. Intensive Care Med. 2013;39(10):1839–42.
2. Schouten M, Wiersinga WJ, Levi M, van der Poll T. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol. 2008;83(3):536–45.
3. Ryan US, Ryan JW, Whitaker C, Chiu A. Localization of angiotensin converting enzyme (kininase II, II. Immunocytochemistry and immunofluorescence. Tissue Cell. 1976;8(1):125–45.
4. Chawla LS, Busse LW, Brash-Mitchell E, Alothabi Z. The use of angiotensin II in distributive shock. Crit Care. 2016;20(1):137.
5. Zhang W, Chen X, Huang L, Lu N, Zhou L, Wu G, et al. Severe sepsis: Low expression of the renin-angiotensin system is associated with poor prognosis. Exp Ther Med. 2014;7(5):1342–8.
6. Orfanos SE, Armaganidis A, Glykos N, Pauvdi E, Kaltsa P, Sarafidou P, et al. Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in acute lung injury. Circulation. 2000;102(16):2011–8.
7. Deitz DM, Swartz KB, Wright M, Murphy E, Connell RS, Harrison MW. Effects of E. coli endotoxin on rat plasma angiotensin converting enzyme activity in vitro and in vivo. Circ Shock. 1987;21(1):23–9.
8. Hollinger MA. Effect of endotoxin on mouse serum angiotensin-converting enzyme. Am Rev Respir Dis. 1983;127(6):756–7.
9. du Cheyron D, Fradin S, Ramakers M, Terzi N, Guillotin D, Bouchet B, et al. Angiotensin converting enzyme insertion/deletion genetic polymorphism: its impact on renal function in critically ill patients. Crit Care Med. 2008;36(12):3778–83.
10. Yang H, Wang Y, Liu L, Hu Q. Increased susceptibility of sepsis associated with CD143 deletion/insertion polymorphism in Caucasians: a meta analysis. Int J Clin Exp Pathol. 2014;7(10):6551–8.
11. Luque M, Martin P, Martell N, Fernandez C, Brosnihan KB, Ferrario CM. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1–7) in essential hypertension. J Hypertens. 1996;14(6):799–805.
12. Wunderink RA, Albertson TE, Busse L, Deane AM, Khanna A, McCurdy MT, et al. Baseline angiotensin levels and ACE effects in patients with vasodilatory shock treated with angiotensin II. Intensive Care Med Exp. 2017;5(Suppl 2):0703.
13. Ferrario CM, Brosnihan KB, Diz DI, Jaswal N, Khosla MC, Milsted A, et al. Angiotensin-(1–7): a new hormone of the angiotensin system. Hypertension. 1991;18(5 Suppl):II126–33.
14. Cockcroft JR, Chowienczyk PJ, Brett SE, Bender N, Ritter JM. Inhibition of bradykinin-induced vasodilation in human forearm vasculature by icatibant, a potent B2-receptor antagonist. Br J Clin Pharmacol. 1994;38(4):317–21.
15. Margolius HS, Kallikreins and kinins. Molecular characteristics and cellular and tissue responses. Diabetes. 1996;45(Suppl 1):S14–9.
Author/s:
Chawla, LS; Chen, S; Bellomo, R; Tidmarsh, GF

Title:
Angiotensin converting enzyme defects in shock: implications for future therapy

Date:
2018-10-28

Citation:
Chawla, L. S., Chen, S., Bellomo, R. & Tidmarsh, G. F. (2018). Angiotensin converting enzyme defects in shock: implications for future therapy. CRITICAL CARE, 22 (1), https://doi.org/10.1186/s13054-018-2202-y.

Persistent Link:
http://hdl.handle.net/11343/253235

License:
CC BY